- cafead Jun 05, 2024 at 11:32: AM
via Australian radiopharmaceuticals biotech Telix Pharmaceuticals is targeting a $200 million initial public offering in the U.S.
The expected Nasdaq debut consists of 17,000,000 American depositary shares (ADSs), plus a 30-day option for underwriters to purchase up to 15% more ADSs sold in the offering at the initial price, according to a June 5 release.
article source
The expected Nasdaq debut consists of 17,000,000 American depositary shares (ADSs), plus a 30-day option for underwriters to purchase up to 15% more ADSs sold in the offering at the initial price, according to a June 5 release.
article source